Minerva Neurosciences Stock Forecast for 2023 - 2025 - 2030
Updated on 05/17/2024
Minerva Neurosciences Stock Forecast and Price Target
According to experts, who recently provided their 2024 price targets for Minerva Neurosciences, the average price target is $7.00, with a high estimate of $7.00 and a low estimate of $7.00. That is a potential upside of approximately 172.37% from the last closing price of $2.57 on May, 2024. Even if you are not interested in NERV stock, you should be aware of its competitors and their current standings.
172.37% Upside
Minerva Neurosciences Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Minerva Neurosciences's Price has fallen from $6.00 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $2.75 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.35 | Buy/Sell | $178.42 | 9.52% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$314.72 | Buy/Sell | $303.65 | 1.68% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.86 | Buy/Sell | $87.82 | 17.89% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.04 | Buy/Sell | $299.62 | 25.41% |
Minerva Neurosciences Revenue Forecast for 2023 - 2025 - 2030
In the last zero years, Minerva Neurosciences's Revenue has fallen from $41.18M to $41.18M – a 0.00% decrease. According to 1 prominent analysts, Minerva Neurosciences's Revenue will fall by 100.00% in the next year, reaching $0.00. For the next seven years, the forecast is for Revenue to grow by 1630.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$76.97 | Buy/Sell | $111.56 | 43.56% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$56.86 | Buy/Sell | $77.05 | 38.06% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$69.06 | Buy/Sell | $34.00 | 66.52% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$106.64 | Buy/Sell | $85.71 | 12.53% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$10.43 | Buy/Sell | $20.42 | 139.69% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$25.00 | Buy/Sell | $52.00 | 120.00% |
Minerva Neurosciences EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Minerva Neurosciences's EBITDA has gone down from $1.86M to $-23.11M – a 1342.47% drop. For the next year, analysts predict that EBITDA will reach $-35.98M – an increase of 55.70%. Over the next seven years, experts believe that Minerva Neurosciences's EBITDA will grow at a rate of 79.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$9.50 | Buy/Sell | $17.90 | 89.47% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$39.94 | Buy/Sell | $63.29 | 77.77% |
Minerva Neurosciences EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Minerva Neurosciences's EBIT has fallen from $1.85M to $-23.12M – a 1349.73% decrease. In the next year, analysts predict that EBIT will jump to $-24.92M – up 7.79% from the current level. Professionals believe that By 2030, Minerva Neurosciences's EBIT will fall to $417.93M – a 1907.66% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$14.85 | Buy/Sell | $33.78 | 88.55% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.61 | Buy/Sell | $42.58 | 17.62% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$9.06 | Buy/Sell | $6.00 | 10.38% |
Minerva Neurosciences EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Minerva Neurosciences's EPS has fallen from $0.40 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $-3.44 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$7.79 | Buy/Sell | $9.94 | 79.72% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$35.00 | Buy/Sell | $40.00 | 27.14% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.28 | Buy/Sell | $25.00 | 121.63% |
Site Navigation
.jpg)